Search

Your search keyword '"Im, S-A."' showing total 1,649 results
Start Over Author "Im, S-A."
1,649 results on '"Im, S-A."'

1. Effects of Nursing Program in Preventing Incontinence-Associated Dermatitis by Applying Zinc Oxide and Petroleum Jelly Skin Protection Products Among Older Patients in Semi-Intensive Medical Care Units: A Pilot Study

Author

Sommana C, Banharak S, Sim-Im S, and Ransinyo K

Subjects
nursing program, incontinence-associated dermatitis, older patient, skin care, critical care, Medicine (General), R5-920
Abstract

Chakkarin Sommana,1 Samoraphop Banharak,1 Supin Sim-Im,2 Khanisorn Ransinyo1 1Department of Gerontological Nursing, Faculty of Nursing, Khon Kaen University, Khon Kaen, Thailand; 2Nursing Department, Srinagarind Hospital, Khon Kaen University, Khon Kaen, ThailandCorrespondence: Samoraphop Banharak, Email sbanharak@kku.ac.thAim: Incontinence-associated dermatitis is a common health problem among older clinical patients, causing related severe skin damage such as pressure ulcers, secondary infection, and long length of hospital stay. This pilot study aimed to develop and examine the effects of nursing programs in preventing incontinence-associated dermatitis (IAD) among older patients. Ten older patients at high risk of incontinence-associated dermatitis were included in this study: five patients received a nursing program combined with mixed products, and another five received a nursing program combined with separate use of products. The program was evaluated using a perianal assessment tool (PAT-T) for risk assessment, the incontinence-associated dermatitis invention tool (IADIT-T) for severity assessment, the skin surface pH, and skin surface moisture. The results revealed that the nursing program and skin products are usable and acceptable, provide step-by-step details, and are simple and easy to follow. The nursing program combined with using zinc oxide products followed by petroleum jelly can prevent and decrease the severity of incontinence-associated dermatitis in older patients. Moreover, it can also improve the skin surface pH to a mild acidity appropriate for the skin condition and increase the skin’s moisture better the nursing program with mixed skin products. This pilot study confirmed that the developed program can be applied in practice. Moreover, the program could be used to decrease the incidence of IAD and skin surface pH but increase skin moisture. However, future study with a larger sample size and applying a more substantial research design for more accuracy and generalization is needed.Clinical Trial Registration Number: OSF https://osf.io/8gj3d.Keywords: nursing program, incontinence-associated dermatitis, older patient, skin care, critical care

Published
2024

2. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

Author

Dent, R., André, F., Gonçalves, A., Martin, M., Schmid, P., Schütz, F., Kümmel, S., Swain, S.M., Bilici, A., Loirat, D., Villalobos Valencia, R., Im, S.-A., Park, Y.H., De Laurentis, M., Colleoni, M., Guarneri, V., Bianchini, G., Li, H., Kirchmayer Machackova, Z., Mouta, J., Deurloo, R., Gan, X., Fan, M., Mani, A., Swat, A., and Cortés, J.

Published
2024
Full Text
View/download PDF

3. The cosmic ray energetics and mass for the international space station (ISS-CREAM) instrument

Author

Yoon, Y.S., Amare, Y., Angelaszek, D., Anthony, N., Cheryian, K., Choi, G.H., Copley, M., Coutu, S., Derome, L., Eraud, L., Hagenau, L., Han, J.H., Huh, H.G., Hwang, Y.S., Hyun, H.J., Im, S., Jeon, H.B., Jeon, J.A., Jeong, S., Kang, S.C., Kim, H.J., Kim, K.C., Kim, M.H., Lee, H.Y., Lee, J., Lee, M.H., Liang, J., Lu, L., Lutz, L., Menchaca-Rocha, A., Mitchell, J.W., Mognet, S.I., Morton, S., Nester, M., Nutter, S., Park, H., Park, I.H., Park, J.M., Picot-Clémente, N., Seo, E.S., Smith, J.R., Walpole, P., Weinmann, R.P., Wu, J., and Zhang, H.G.

Published
2024
Full Text
View/download PDF

5. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

Author

Park, K.H., Loibl, S., Sohn, J., Park, Y.H., Jiang, Z., Tadjoedin, H., Nag, S., Saji, S., Md. Yusof, M., Villegas, E.M.B., Lim, E.H., Lu, Y.-S., Ithimakin, S., Tseng, L.-M., Dejthevaporn, T., Chen, T.W.-W., Lee, S.C., Galvez, C., Malwinder, S., Kogawa, T., Bajpai, J., Brahma, B., Wang, S., Curigliano, G., Yoshino, T., Kim, S.-B., Pentheroudakis, G., Im, S.-A., Andre, F., Ahn, J.B., and Harbeck, N.

Published
2024
Full Text
View/download PDF

7. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

Author

Hortobagyi, G.N., Lacko, A., Sohn, J., Cruz, F., Ruiz Borrego, M., Manikhas, A., Hee Park, Y., Stroyakovskiy, D., Yardley, D.A., Huang, C.-S., Fasching, P.A., Crown, J., Bardia, A., Chia, S., Im, S.-A., Martin, M., Loi, S., Xu, B., Hurvitz, S., Barrios, C., Untch, M., Moroose, R., Visco, F., Parnizari, F., Zarate, J.P., Li, Z., Waters, S., Chakravartty, A., and Slamon, D.

Published
2024
Full Text
View/download PDF

9. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer

Author

Im, S.-A., Gennari, A., Park, Y.H., Kim, J.H., Jiang, Z.-F., Gupta, S., Fadjari, T.H., Tamura, K., Mastura, M.Y., Abesamis-Tiambeng, M.L.T., Lim, E.H., Lin, C.-H., Sookprasert, A., Parinyanitikul, N., Tseng, L.-M., Lee, S.-C., Caguioa, P., Singh, M., Naito, Y., Hukom, R.A., Smruti, B.K., Wang, S.-S., Kim, S.B., Lee, K.-H., Ahn, H.K., Peters, S., Kim, T.W., Yoshino, T., Pentheroudakis, G., Curigliano, G., and Harbeck, N.

Published
2023
Full Text
View/download PDF

10. Chemical Chaperones to Inhibit Endoplasmic Reticulum Stress: Implications in Diseases

Author

Jeon JH, Im S, Kim HS, Lee D, Jeong K, Ku JM, and Nam TG

Subjects
endoplasmic reticulum stress, unfolded protein response, chemical chaperone, drug discovery, diabetes, cardiovascular disease, neurodegeneration, lysosomal storage disease, Therapeutics. Pharmacology, RM1-950
Abstract

Jae-Ho Jeon,1,* Somyoung Im,1,* Hyo Shin Kim,1 Dongyun Lee,1 Kwiwan Jeong,2 Jin-Mo Ku,2 Tae-Gyu Nam1 1Department of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University ERICA campus, Ansan, Gyeonggi-do, 15588, Republic of Korea; 2Gyeonggi Bio-Center, Gyeonggido Business and Science Accelerator, Suwon, Gyeonggi-do, 16229, Republic of Korea*These authors contributed equally to this workCorrespondence: Tae-Gyu Nam, Tel +82-31-400-5807, Fax +82-31-400-5958, Email tnam@hanyang.ac.krAbstract: The endoplasmic reticulum (ER) is responsible for structural transformation or folding of de novo proteins for transport to the Golgi. When the folding capacity of the ER is exceeded or excessive accumulation of misfolded proteins occurs, the ER enters a stressed condition (ER stress) and unfolded protein responses (UPR) are triggered in order to rescue cells from the stress. Recovery of ER proceeds toward either survival or cell apoptosis. ER stress is implicated in many pathologies, such as diabetes, cardiovascular diseases, inflammatory diseases, neurodegeneration, and lysosomal storage diseases. As a survival or adaptation mechanism, chaperone molecules are upregulated to manage ER stress. Chemical versions of chaperone have been developed in search of drug candidates for ER stress-related diseases. In this review, synthetic or semi-synthetic chemical chaperones are categorized according to potential therapeutic area and listed along with their chemical structure and activity. Although only a few chemical chaperones have been approved as pharmaceutical drugs, a dramatic increase in literatures over the recent decades indicates enormous amount of efforts paid by many researchers. The efforts warrant clearer understanding of ER stress and the related diseases and consequently will offer a promising drug discovery platform with chaperone activity.Keywords: endoplasmic reticulum stress, unfolded protein response, chemical chaperone, drug discovery, diabetes, cardiovascular disease, neurodegeneration, lysosomal storage disease

Published
2022

14. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

Author

Turner, N. C., Im, S.-A., Saura, C., Juric, D., Loibl, S., Kalinsky, K., Schmid, P., Loi, S., Sunpaweravong, P., Musolino, A., Li, H., Zhang, Q., Nowecki, Z., Leung, R., Thanopoulou, E., Shankar, N., Lei, G., Stout, T. J., Hutchinson, K. E., and Schutzman, J. L.

Subjects
*EPIDERMAL growth factor receptors, *BREAST cancer, *POISONS, *METASTATIC breast cancer, *PHOSPHATIDYLINOSITOL 3-kinases
Abstract

BACKGROUND Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the pllO catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CÄ) that also promotes the degradation of mutated pllOa. Inavolisib plus palbociclib-fulvestrant has shown synergistic activity in preclinical models and promising antitumor activity in early-phase trials. METHODS In a phase 3, double-blind, randomized trial, we compared first-line inavolisib (at an oral dose of 9 mg once daily) plus palbociclib-fulvestrant (inavolisib group) with placebo plus palbociclib-fulvestrant (placebo group) in patients with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who had had relapse during or within 12 months after the completion of adjuvant endocrine therapy. The primary end point was progression-free survival as assessed by the investigator. RESULTS A total of 161 patients were assigned to the inavolisib group and 164 to the placebo group; the median follow-up was 21.3 months and 21.5 months, respectively. The median progression-free survival was 15.0 months (95% confidence interval [CI], 11.3 to 20.5) in the inavolisib group and 7.3 months (95% CI, 5.6 to 9.3) in the placebo group (hazard ratio for disease progression or death, 0.43; 95% CI, 0.32 to 0.59; P<0.001). An objective response occurred in 58.4% of the patients in the inavolisib group and in 25.0% of those in the placebo group. The incidence of grade 3 or 4 neutropenia was 80.2% in the inavolisib group and 78.4% in the placebo group; grade 3 or 4 hyperglycemia, 5.6% and 0%, respectively; grade 3 or 4 stomatitis or mucosal inflammation, 5.6% and 0%; and grade 3 or 4 diarrhea, 3.7% and 0%. No grade 3 or 4 rash was observed. Discontinuation of any trial agent because of adverse events occurred in 6.8% of the patients in the inavolisib group and in 0.6% of those in the placebo group. CONCLUSIONS In patients with PIKJCA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib-fulvestrant led to significantly longer progression-free survival than placebo plus palbociclib-fulvestrant, with a greater incidence of toxic effects. The percentage of patients who discontinued any trial agent because of adverse events was low. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11)

Author

Cho, E.H., Kim, J.-Y., Im, S.-A., Jung, K.H., Sohn, J., Lee, K.S., Chae, Y.S., Lee, K.H., Kim, J.H., Jang, J.-H., Ahn, J.H., Park, M.S., Lee, S.-Y., and Park, Y.H.

Published
2021
Full Text
View/download PDF

17. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Author

Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J.P., Taran, T., and Fasching, P.A.

Published
2021
Full Text
View/download PDF

18. 261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Author

Schmid, P, Oliveira, M, O'Shaughnessy, J, Cristofanilli, M, Graff, SL, Im, S-A, Loi, S, Saji, S, Wang, S, Cescon, DW, Hovey, T, Nawrot, A, Tse, K, Vukovic, P, Curigliano, G, Schmid, P, Oliveira, M, O'Shaughnessy, J, Cristofanilli, M, Graff, SL, Im, S-A, Loi, S, Saji, S, Wang, S, Cescon, DW, Hovey, T, Nawrot, A, Tse, K, Vukovic, P, and Curigliano, G

Published
2024

20. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Author

Park, Y.H., Senkus-Konefka, E., Im, S.-A., Pentheroudakis, G., Saji, S., Gupta, S., Iwata, H., Mastura, M.Y., Dent, R., Lu, Y.-S., Yin, Y., Smruti, B.K., Toyama, T., Malwinder, S., Lee, S.C., Tseng, L.-M., Kim, J.H., Kim, T.-Y., Suh, K.J., Cardoso, F., Yoshino, T., and Douillard, J.-Y.

Published
2020
Full Text
View/download PDF

22. On-orbit performance of the top and bottom counting detectors for the ISS-CREAM experiment on the international space station

Author

Kang, S.C., Amare, Y., Anderson, T., Angelaszek, D., Anthony, N., Cheryian, K., Choi, G.H., Copley, M., Coutu, S., Derome, L., Eraud, L., Hagenau, L., Han, J.H., Huh, H.G., Hwang, Y.S., Hyun, H.J., Im, S., Jeon, H.B., Jeon, J.A., Jeong, S., Kim, H.J., Kim, K.C., Kim, M.H., Lee, H.Y., Lee, J., Lee, M.H., Liang, J., Link, J.T., Lu, L., Lundquist, J.P., Lutz, L., Menchaca-Rocha, A., Mernik, T., Mitchell, J.W., Mognet, S.I., Morton, S., Nester, M., Nutter, S., Ofoha, O., Park, H., Park, I.H., Park, J.M., Picot-Clemente, N., Quinn, R., Seo, E.S., Smith, J.R., Takeishi, R., Walpole, P., Weinmann, R.P., Wu, J., and Yoon, Y.S.

Published
2019
Full Text
View/download PDF

23. Star-Formation Bimodality in Early-Type Galaxies

Author

Amblard, A., Riguccini, L., Temi, P., Im, S., Fanelli, M., and Serra, P.

Subjects
Astrophysics - Cosmology and Nongalactic Astrophysics
Abstract

We compute the properties of a sample of 221 local early-type galaxies with a spectral energy distribution (SED) modeling software, CIGALEMC. Concentrating on the star forming activity and dust contents, we derive parameters such as the specific star formation rate, the dust luminosity, dust mass and temperature. 52 % of our sample is composed of elliptical (E) galaxies and 48 % of lenticular (S0) galaxies. We find a larger proportion of S0 galaxies among galaxies with a large specific star formation rate (sSFR) and large specific dust emission. The stronger activity of S0 galaxies is confirmed by larger dust masses. We investigate the relative proportion of active galactic nuclei (AGN) and star-forming (SF) galaxies in our sample using spectroscopic SDSS data and near-infrared selection techniques, and find a larger proportion of AGN dominated galaxy in the S0 sample than the E one. This could corroborate a scenario where blue galaxies evolve into red ellipticals by passing through a S0 AGN active period while quenching its star formation. Finally, we find a good agreement comparing our estimates with color indicators., Comment: 32 pages, 14 figures, accepted in ApJ

Published
2013
Full Text
View/download PDF

24. The ISS-CREAM Silicon Charge Detector for identification of the charge of cosmic rays up to Z = 26: Design, fabrication and ground-test performance

Author

Lee, J., Amare, Y., Anderson, T., Angelaszek, D., Anthony, N., Cheryian, K., Choi, G.H., Copley, M., Coutu, S., Derome, L., Eraud, L., Hagenau, L., Han, J.H., Hong, G., Huh, H.G., Hwang, Y.S., Hyun, H.J., Im, S., Jeon, H.B., Jeon, J.A., Jeong, S., Kang, S.C., Kim, H.J., Kim, K.C., Kim, M.H., Lee, H.Y., Lee, M.H., Liang, J., Link, J.T., Lu, L., Lutz, L., Menchaca-Rocha, A., Mernik, T., Mitchell, J.W., Mognet, S.I., Morton, S., Nester, M., Nutter, S., Ofoha, O., Park, H., Park, I.H., Park, J.M., Picot-Clemente, N., Quinn, R., Seo, E.S., Smith, J.R., Walpole, P., Weinmann, R.P., Wu, J., and Yoon, Y.S.

Published
2019
Full Text
View/download PDF

25. The boronated scintillator detector of the ISS-CREAM experiment

Author

Amare, Y., Anderson, T., Angelaszek, D., Anthony, N., Cheryian, K., Choi, G.H., Copley, M., Coutu, S., Derome, L., Eraud, L., Hagenau, L., Han, J.H., Huh, H.G., Hwang, Y.S., Hyun, H.J., Im, S., Jeon, H.B., Jeon, J.A., Jeong, S., Kang, S.C., Kim, H.J., Kim, K.C., Kim, M.H., Lee, H.Y., Lee, J., Lee, M.H., Liang, J., Link, J.T., Lu, L., Lutz, L., Menchaca-Rocha, A., Mernik, T., Mitchell, J.W., Mognet, S.I., Morton, S., Nester, M., Nutter, S., Ofoha, O., Park, H., Park, I.H., Park, J.M., Picot-Clémente, N., Quinn, R., Seo, E.S., Smith, J.R., Walpole, P., Weinmann, R.P., Wu, J., and Yoon, Y.S.

Published
2019
Full Text
View/download PDF

26. Measurement of delayed fluorescence in plastic scintillator from 1 to 10 [formula omitted]

Author

Nutter, S., Amare, Y., Anderson, T., Angelaszek, D., Anthony, N., Cheryian, k., Choi, G.H., Copley, M., Coutu, S., Derome, L., Eraud, L., Hagenau, L., Han, J.H., Huh, H.G., Hwang, Y.S., Hyun, H.J., Im, S., Jeon, H.B., Jeon, J.A., Jeong, S., Kang, S.C., Kim, H.J., Kim, K.C., Kim, M.H., Lee, H.Y., Lee, J., Lee, M.H., Liang, J., Link, J.T., Lu, L., Lutz, L., Menchaca-Rocha, A., Mernik, T., Mitchell, J.W., Mognet, S.I., Morton, S., Nester, M., Ofoha, O., Park, H., Park, I.H., Park, J.M., Picot-Clémente, N., Quinn, R., Seo, E.S., Smith, J.R., Walpole, P., Weinmann, R.P., Wu, J., and Yoon, Y.S.

Published
2019
Full Text
View/download PDF

28. Theory of plasmon-enhanced high-harmonic generation in the vicinity of metal nanostructures in noble gases

Author

Husakou, A., Im, S. -J., and Herrmann, J.

Subjects
Physics - Optics
Abstract

We present a semiclassical model for plasmon-enhanced high-harmonic generation (HHG) in the vicinity of metal nanostructures. We show that both the inhomogeneity of the enhanced local fields and electron absorption by the metal surface play an important role in the HHG process and lead to the generation of even harmonics and to a significantly increased cutoff. For the examples of silver-coated nanocones and bowtie antennas we predict that the required intensity reduces by up to three orders of magnitudes and the HHG cutoff increases by more than a factor of two. The study of the enhanced high-harmonic generation is connected with a finite-element simulation of the electric field enhancement due to the excitation of the plasmonic modes., Comment: 4 figures

Published
2010
Full Text
View/download PDF

29. A simulation study of Top and Bottom Counting Detectors in ISS-CREAM experiment for cosmic ray electron physics

Author

Park, J.M., Amare, Y., Anderson, T., Angelaszek, D., Anthony, N., Arnold, H., Choi, G.H., Copley, M., Coutu, S., Derome, L., Ebongue, C., Eraud, L., Faddis, I., Han, J.H., Howley, I.J., Huh, H.G., Hwang, Y.S., Hyun, H.J., Im, S., Jeon, H.B., Jeon, J.A., Jeong, S., Kang, S.C., Kim, D.Y., Kim, H.J., Kim, K.C., Kim, M.H., King, P., Lee, H.Y., Lee, J., Lee, M.H., Liang, J., Link, J.T., Lutz, L., Menchaca-Rocha, A., Mitchell, J.W., Morton, S., Nester, M., Nutter, S., Ofoha, O., Park, H., Park, I.H., Picot-Clemente, N., Seo, E.S., Smith, J.R., Walpole, P., Weinmann, R.P., Wu, J., Yon, B., and Yoon, Y.S.

Published
2018
Full Text
View/download PDF

30. A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

Author

Pivot, X., Bondarenko, I., Nowecki, Z., Dvorkin, M., Trishkina, E., Ahn, J.-H., Im, S.-A., Sarosiek, T., Chatterjee, S., Wojtukiewicz, M.Z., Shparyk, Y., Moiseyenko, V., Bello, M., III, Semiglazov, V., Lee, Y., and Lim, J.

Published
2018
Full Text
View/download PDF

37. HERITAGE DATA VISUALISATION SERVICE FOR MUSEUM STAKEHOLDERS

Author

Shin, H., Im, S., and Lee, J.

Abstract

The goal of this study was to help cultural heritage administrators, curators and museum visitors apply their understanding and knowledge of artefacts in the museum and the correlations between their embedded contexts appropriately in their work and roles. This study developed the Artefact Data Management Programme and the Artefact Data Visualisation Programme specialised in cultural heritage so people can quickly and easily access the desired information through the correlations between artefacts. The Artefact Data Management Programme combines a Windows-based data converter programme and an artefact management programme that can import and utilise the files converted by the programme. Through the Artefact Data Management Programme, users can enter, modify and delete sub-attributes to manage them. Moreover, this study also allows curators to plan exhibitions from a new perspective through the Artefact Data Visualisation Programme, which converts the entered attribute information of the artefacts into visualised content and edits it. Incidentally, visitors who are non-experts can also understand the relationship between artefacts and learn information through this webpage. In conclusion, the ultimate goal of this study was to produce useful programmes that could help museum stakeholders to edit and utilise cultural heritage data.

Published
2023

41. 190MO Association of 18-Gene expression profile (GEP) with clinical outcomes in patients with metastatic triple-negative breast cancer (mTNBC) treated with pembrolizumab (Pembro) or chemotherapy (Chemo) in KEYNOTE-119

Author

Cortés, J., primary, Lipatov, O., additional, Im, S-A., additional, Gonçalves, A., additional, Lee, K.S., additional, Schmid, P., additional, Tamura, K., additional, Testa, L., additional, Ohtani, S., additional, Harbeck, N., additional, Loi, S., additional, Salgado, R.F., additional, Lunceford, J., additional, Karantza, V., additional, Mejia, J.A., additional, Cristescu, R., additional, Nebozhyn, M., additional, Jelinic, P., additional, Huang, L., additional, and Winer, E.P., additional

Published
2023
Full Text
View/download PDF

43. 191MO KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs

Author

Rugo, H.S., primary, Cescon, D.W., additional, Im, S-A., additional, Yusof, M. Md, additional, Araneda, C.E. Gallardo, additional, Lipatov, O., additional, Cruz, F., additional, Barrios, C.H., additional, Hegg, R., additional, Martín, E. Holgado, additional, Torregroza Otero, M.A., additional, Turner, N., additional, Árkosy, P.F., additional, Tarnawski, R., additional, Karantza, V., additional, Pan, W., additional, Guo, Z., additional, and Cortés, J., additional

Published
2023
Full Text
View/download PDF

44. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving frst-line ribociclib plus fulvestrant

Author

Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CTS151: Bioquímica médica., Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S. A., Cruz Merino, Luis de la, Slamon, D. J., Universidad de Sevilla. Departamento de Medicina, Universidad de Sevilla. CTS151: Bioquímica médica., Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S. A., Cruz Merino, Luis de la, and Slamon, D. J.

Abstract

Background The phase III MONALEESA-3 trial included frst- (1L) and second-line (2L) patients and demonstrated a signifcant overall survival (OS) beneft for ribociclib+fulvestrant in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) in the fnal protocol-specifed and exploratory (longer follow-up) OS analyses. At the time of these analyses, the full OS beneft of 1L ribociclib was not completely characterized because the median OS (mOS) was not reached. As CDK4/6 inhibi‑ tor (CDK4/6i)+endocrine therapy (ET) is now a preferred option for 1L HR+/HER2− ABC, we report an exploratory analysis (median follow-up, 70.8 months; 14.5 months longer than the prior analysis) to fully elucidate the OS beneft in the MONALEESA-3 1L population. Methods Postmenopausal patients with HR+/HER2− ABC were randomized 2:1 to 1L/2L fulvestrant+riboci‑ clib or placebo. OS in 1L patients (de novo disease or relapse>12 months from completion of [neo]adjuvant ET) was assessed by Cox proportional hazards model and Kaplan–Meier methods. Progression-free survival 2 (PFS2) and chemotherapy-free survival (CFS) were analyzed. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615). Results At data cutof (January 12, 2022; median follow-up time, 70.8 months), mOS was 67.6 versus 51.8 months with 1L ribociclib versus placebo (hazard ratio (HR) 0.67; 95% CI 0.50–0.90); 16.5% and 8.6% of ribociclib and placebo patients, respectively, were still receiving treatment. PFS2 (HR 0.64) and CFS (HR 0.62) favored ribociclib versus pla‑ cebo. Among those who discontinued treatment, 16.7% and 35.0% on ribociclib or placebo, respectively, received a subsequent CDK4/6i. No new safety signals were observed. This analysis of MONALEESA-3 reports the longest mOS thus far (67.6 months) for 1L patients in a phase III ABC trial. These results in a 1L population show that the OS beneft of ribociclib was maintained through extended follow-u

Published
2023

45. Analysis of the feasibility of the irish climate action plan using TIMES modelling platform and QGIS geospatial software

Author

Universitat Politècnica de Catalunya. Departament d'Enginyeria Química, Akademia Górniczo-Hutnicza im. S. Staszica w Krakowie, Valderrama Ángel, César Alberto, Wyrwa, Artur, Clogher, Richard, Universitat Politècnica de Catalunya. Departament d'Enginyeria Química, Akademia Górniczo-Hutnicza im. S. Staszica w Krakowie, Valderrama Ángel, César Alberto, Wyrwa, Artur, and Clogher, Richard

Abstract

Analysis of the Feasibility of the Irish Climate Action Plan Using TIMES Modelling Platform and QGIS Geospatial Software

Published
2023

46. N.S. TRUBETSKOI AND THE PRAGUE LINGUISTIC SCHOOL

Author

null Im S.

Abstract

The paper considers those positive moments that were achieved in the works of N.S. Trubetskoi in morphonology, as well as the disadvantages that did not allow morphonology to be distinguished as an independent linguistic discipline. The views of N.S. Trubetskoi were further developed by the Prague Linguistic School. However, they failed to resolve the issue of the independent status of morphonology as a linguistic discipline, although they tried to single out independent morphonological units – morphoneme and alternant. KEY WORDS: morphonology, alternant, alternation, morphoneme.

Published
2022

48. Performances of photodiode detectors for top and bottom counting detectors of ISS-CREAM experiment

Author

Hyun, H.J., Anderson, T., Angelaszek, D., Baek, S.J., Copley, M., Coutu, S., Han, J.H., Huh, H.G., Hwang, Y.S., Im, S., Jeon, H.B., Kah, D.H., Kang, K.H., Kim, H.J., Kim, K.C., Kwashnak, K., Lee, J., Lee, M.H., Link, J.T., Lutz, L., Mitchell, J.W., Nutter, S., Ofoha, O., Park, H., Park, I.H., Park, J.M., Patterson, P., Seo, E.S., Wu, J., and Yoon, Y.S.

Published
2015
Full Text
View/download PDF

50. Gated-Dynode Photomultiplier Tube Assembly for the Boronated Scintillator Detector of the ISS-CREAM Experiment

Author

Anderson, T, Chen, Y, Coutu, S, Im, S, LaBree, T, Link, Jason T, Mitchell, John W, Mognet, S, Nutter, S, Wallace, K, Yin, Z, and Yu, M

Subjects
Astrophysics
Abstract

We present the design of a four-photomultiplier tube (PMT) assembly for measuring light generation in theBoronated Scintillator Detector (BSD) of the Cosmic Ray Energetics And Mass experiment for the InternationalSpace Station (ISS-CREAM). The light produced in the scintillator includes a contribution from the captureof thermalized neutrons produced in cosmic ray interactions, as well as delayed fluorescence, in the range ofseveral microseconds following the incident cosmic ray impact. The BSD is held in an insensitive state until acosmic-ray trigger causes a rapid turn on of the PMTs to detect late light signals, several microseconds afterthe trigger. The design includes two pulsed high-voltage supplies, which serve to gate the first two dynodesof the Hamamatsu R1924A PMTs used in the assembly. When the dynode gates are held in the "off" state,this scheme is shown to suppress >105 photons from injection into the tube's multiplier stage, while beingcapable of rapid switching into a stable operating mode in less than 1 s. This mitigates any backgroundsfrom afterpulsing that might otherwise be present in the PMT response following the cosmic ray incidence.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results